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Summary.-Prostaglandin (PG) E2 biosynthesis in Yoshida hepatoma (AH 130) was
evaluated by radioimmunoassay. When hepatoma cells were incubated in vitro, the
levels of PGE2 in the medium were similar to those found in hepatocytes for the first
2 h; this was followed by a rapid increase in PGE2 formation, and the 6h incubation
levels were 4-fold higher than in hepatocytes.
Addition of sodium arachidonate markedly and dose-dependently stimulated
PGE2 synthesis; the increase was largely prevented by the addition of indomethacin
(1 um) or L 8027, a prostaglandin synthetase inhibitor.
Experiments in vivo indicated that indomethacin treatment of tumour-bearing
rats significantly reduced the tumour mass. When rats were injected with PGE2
after receiving the drug, the number of tumour cells was very similar to that of
untreated animals. This, as well as the inhibition of tumour growth by acetyl-
salicylic acid, strongly suggests that the inhibition of PG biosynthesis by anti-
inflammatory drugs and the inhibition of tumour proliferation may be closely
associated events. It was also found that injections of indomethacin very significantly
prolonged survival of hepatoma-bearing rats.
Since PGE2 does not appear to affect the cyclic AMP levels of hepatoma cells, it is
possible that hepatoma may use PGE2 to subvert the immune system. This could
help to explain the effectiveness of anti-inflammatory drugs in the control of tumour
growth.
BY SHOWING RAISED LEVELS of prosta-
glandins (PGs) in tumours and plasma of
tumour-bearing patients, Karim (1976)
opened up the way to studies which have
extended these findings to several human
and animal tumours. In addition, using
cultured cells, it has been found that
transformation by carcinogens (Hong et
al., 1977; Levine & Hong, 1977) or by
viruses (Hammarstrom, 1977) is followed
by increased production of PGs.
It is difficult to correlate these findings
with claims that PGs inhibit tumour
growth in vitro or in vivo (Santoro et al.,
1976). On the other hand, Plescia et al.
(1975) have suggested that PGs may be
used by tumours to subvert the immune
system. This hypothesis also accords with
the marked sensitivity of lymphocytes as
well as macrophages to PGE which, by
increasing cyclic AMP levels, antagonizes
mitogen-induced cell proliferation or
cytotoxicity (Pelus & Strausser, 1977;
Schultz et al., 1978).
The results reported here indicate that
the rapidly growing cells of Yoshida hepa-
toma produce considerable amounts of
PGE2 (4-fold more than rat hepatocytes)
and that indomethacin or acetylsalicylic
acid strongly reduce the growth of the
tumour in vivo and very significantly
prolong the survival of tumour-bearing
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rats. Thus, increased PGE2 production
seems positively correlated with tumour
growth.
MATERIALS AND METHODS
Materials.-3H-prostaglandin E2 (sp. act.
160 Ci/mmol), G-3H-adenosine 3', 5'-mono-
phosphate (27 Ci/mmol) were obtained from
The Radiochemical Centre, Amersham. Anti-
prostaglandin E2 serum and bovine serum
albumin were products of Sigma Chemical
Co., St Louis, Mo, U.S.A. Silicic acid (200-
400 mesh) was a product of Merck, Darm-
stadt, Germany. The prostaglandins were
kindly providedbyDrJohn Pike, The Upjohn
Company, Kalamazoo, Mich., U.S.A. Indo-
methacin (Sigma Chem. Co., U.S.A.) was
dissolved in Krebs-Henseleit solution and a
few drops of IN NaOH; L 8027 was provided
by S. A. Labaz, Belgium, this being dissolved
in ethanol and diluted with the incubation
medium. All other chemicals were of the
highest reagent grade commercially available.
Methods.-Male Wistar rats weighing 80-
130 g were used. Yoshida ascites hepatoma
AH 130 (about 20 x 106 cells in 0-5 ml of
ascites fluid at 7 days) was injected i.p. The
tumour-bearing rats were usually killed 7
days later, and in some experiments 4-11
days later. Cells from ascites fluid, washed
twice with 0.9% NaCl, were suspended in
Krebs-Henseleit solution, pH 7-4, containing
2% albumin (0-8-1-0 mg protein or 2-5-
3.2 x 106 cells per ml). Such preparations
contained >90% viable cells, as judged by
the trypan-blue exclusion test and <10%
contaminating cells. At the end ofthe incuba-
tions viability was >80%.
Cell suspensions (1 ml) were incubated at
37°C for the indicated times under gassing
with 95% 02-5% CO2 in the absence or
presence of cold arachidonate (0-1-10-0
,ug/ml). After centrifugation supernates were
acidified to pH 3-5 with 2N formic acid and
PGs were extracted twice with 5 vols ethyl
acetate (recovery >95%). The extracts were
taken to dryness and PGE was purified by
column chromatography using CHC13/
CH30H mixtures as described by Salmon &
Karim (1975) with a recovery 75%. Radio-
immunoassay was carried out as previously
described (Bartolini et al., 1978). The incuba-
tion system contained in a final volume of375
jul: 50-100 ,ul samples or 3-30 pg PGE2; 50 ,d
antiserum binding 55% of labelled ligand;
25 ,d labelled PGE2 (12.5 nCi) and Tris-HCl
(0.05M, pH 7.5). Blanks contained no anti-
serum. Tubes were incubated first for 1 h
at 37TC, then for at least 4 h at4TC. The tubes
were placed in an ice bath and 100 ,u of
freshly prepared albumin-coated charcoal
suspension (100 mg/ml 3% bovine serum
albumin in Tris-HCl 0-05M, pH 7.5) was
quicklyadded and the tubes werevortexedfor
30 s. After standing in ice for 5 min, they
were centrifuged at 2000 g for 5 min. 0-2ml
supernates were counted with 4 ml of Bray
solution. Cross-reactivities were as reported
elsewhere (Bartolini et al., 1978). In addition,
6-keto-PGF1, cross-reacted 3.5% and TxB2
0-01%. The method has a sensitivity of 3 pg,
an accuracy (recovery of PGE2 added to
buffer) >90% and intra- or inter-assay
coefficients of variations < 10%.
PGJ2 was assayed by the platelet aggrega-
tion test, as previously described (Tomasi
et at., 1978). Aliquots (50 ,ul) of washed
hepatoma cells (10-20 mg protein per ml of
buffer) were pre-incubated for 5 min with
0.5 ml human platelet-rich plasma (PRP)
and aggregation was induced with 1 5mM Na
arachidonate. In other experiments cells
were incubated with 0-1mM Na arachidonate
for 10 min at 37TC, cells were removed by
centrifugation and aliquots of the super-
natant solutions were immediately added to
0.5 ml of PRP. Aggregation was induced 2
min later as described above. Cyclic AMP
was measured by the method of Brown et al.
(1971). Proteins were determined by the
Lowry method, using bovine serum albumin
as standard.
Cell counts were performed on a Model
ZBI Coulter Counter (Coulter Electronics,
Hialeah, FL.) equipped with a 100pM
aperture and a 0-5ml manometer. Yoshida
hepatoma cells were counted at settings of
1/amplification = 16 and 1/aperture current =
1/2 with a window of 15-100. The data are
usually the mean of 3 observations. The data
in Fig. 3 were obtained from a control group
(no indomethacin) of 34 rats and an indo-
methacin-treated group of 36 rats.
Statistical analysis was performed by
Student's t test.
RESULTS
Prostaglandin synthesis in the hepatoma
Tumour-cell suspensions (0-8 mg protein
or 2-5 x 106 cells per ml) were incubated
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FIG. 1. Time-course of PGE (0 O) and
of AMP ( x x ) formation in Yoshida
hepatoma cells. 1 ml of cell suspension
containing 0-8 mg protein in Krebs-
Henseleit solution was incubated at 37°C
for 2-5-360 min in a shaking bath. The
supernatants were then acidified to pH 3-5
with formic acid and PGs were extracted
twice with 5 vol of ethylacetate. Extracts
were dried and chromatographed as de-
scribed in the text. PGE was determined
by radioimmunoassay. In parallel tubes the
cAMP content was evaluated by the pro-
tein-binding assay of Brown et al. (1971).
at 37°C for 2-5-360 min and the release
of PGE2 into the medium was evaluated
by radioimmunoassay.
In Fig. 1 it is shown that a slow increase
in PGE2 production was followed after
120 min by a rapid increase in the rate of
synthesis; even after 360 min incubation
the curve failed to reach a plateau. This
is in marked contrast to the results using
hepatocytes (Bartolini et al., 1978) in
which PGE2 production levels off at 60
min and the levels remain even after a 4h
incubation (not shown) at least 4-fold
lower than those in tumour cells.
In addition, during incubation cyclic
AMP levels were determined (Fig. 1). It is
clear that while PGE2 synthesis was
increasing, no modification of cyclic AMP
levels was observed. This, as well as data
indicating that cyclic AMP levels are not
modified when cells are incubated with
PGE2 (1-0-10.0 0 g/ml; not shown) strongly
suggests that PGE2 does not act directly
on the tumour cell, at least as far as cyclic
AMP levels are concerned. This does not
exclude possible actions on the tumour not
mediated by cyclic AMP.
It is well known that endogenous
arachidonate is used as a precursor of
PGE2 and that addition of this fatty acid
stimulates PG synthesis. We found that
addition ofsodium arachidonate to tumour
cells increased PGE2 formation in a dose-
dependent fashion. In the presence of
10 jug of this fatty acid, cells were found
to produce 14 x more PGE2 than in its
absence (not shown). A 4-fold increase in
PGE2 synthesis was noted in the same
conditions using parenchymal cells (Barto-
linietal., 1978).
By using a very sensitive biological
assay for PGI2 and TxA2, the platelet
aggregation test (Moncada et al., 1976), we
found that addition of tumour-cell sus-
pensions to human PRP failed both to
inhibit or to induce (which is indirect
evidence that, at least after short periods
ofincubation, TxA2 is not formed) arachi-
donate-induced aggregation (not shown).
This, as well as the failure ofsupernates of
cells incubated with Na arachidonate to
affect PRP aggregation, strongly suggests
that PGI2 is not formed in significant
amounts, at least after short-term incuba-
tion. We have previously reported (Tomasi
et al., 1978) that liver sinusoidal cells were
capable, in similar experimental con-
ditions, ofinhibiting arachidonate-induced
aggregation.
The effect ofnon-steroidalanti-inflammatory
drugs on the growth rate
In Fig. 2 it is shown that indomethacin
(1.0 puM) in vitro markedly inhibits PGE2
formation, especially at the highest dose
of arachidonate used. L 8027, a PG
synthetase inhibitor, behaved more or
less like indomethacin (Fig. 2). Although
L 8027 was reported to be a selective
TxA2 synthetase inhibitor in platelets
(Gryglewski et al., 1977) our data indicate
that it may behave also as a potent PG
synthetase inhibitor, at least in this
hepatoma. It is unlikely that we are
measuring TxB2 formation since: (a) the
platelet aggregation test gave no indica-
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FIG. 2. The effect of 10-6M indomethacin
(A) and L 8027 (U) on the biosynthesis of
PGE in Yoshida hepatoma cells. Incuba-
tions were carried out for 45 min at 370C.
20 1A of Na arachidonate dissolved in 2%
Na2CO3 was added to each tube. Controls
(0) received 20 ,ll of solvent. Details are
described in the text and in the legend to
Fig. 1.
tion of its formation; (b) TxB2 cross-
reacts very little (<0-01%) with our
antibodies.
These data prompted us to test its effect
on tumour growth rate in vivo. Two groups
of rats were injected with tumour cells
and tumour cells plus indomethacin (1 mg/
kg body wt) respectively. The drug was
then administered twice a day and rats
were killed 4-11 days after tumour
implants. In Fig. 3 it is shown that in
rats injected with indomethacin there was
a dramatic reduction in the total number
of tumour cells as evaluated by a Coulter
Counter, both during the exponential and
stationary phases ofgrowth.
To establish whether growth rate is
slowed down or proliferation blocked after
indomethacin treatment requires a dif-
ferent experimental approach. That this
effect of indomethacin is very probably
connected with its ability to inhibit
PG biosynthesis is supported by experi-
ments showing that acetylsalicylic acid
has an effect very like that of indo-
methacin. This drug, injected i.p. at a
dose of 10-0 mg/kg body wt once a day,
appears markedly to inhibit tumour mass,
atleast atthe 7thdayaftertumourimplan-
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FIo. 3. The effect of indomethacin (0) on
the proliferation of Yoshida hepatoma
cells. Tumour cells (20 x 106) were injected
i.p. into 2 groups of rats of the same age
(±5 days) and sex. One group received
indomethacin twice a day i.p. (1 mg/kg
body wt). The second group (0) served as
control and received the same amount of
the diluent. On the days indicated, 4-6 rats
from each group were killed. The ascites
fluid (ascites plasma plus tumour cells) was
withdrawn by a syringe and the pern-
toneal cavity opened and thoroughly
washed with known volumes of ice-cold
0.9% NaCl. Cells were counted with a
Coulter Counter. Tumour mass is expressed
as mean cell number + s.e.
tation (not shown). This low dose is
probably effective because it is acting
directly on the hepatoma cells in the
peritoneal cavity.
Further and more direct evidence was
obtained by injecting i.p. PGE2 (1 mg/kg)
into tumour-bearing, indomethacin-
treated rats. It was found (Fig. 4) that
PGE2 was capable of counteracting the
inhibition of growth due to the drug,
making the growth rate indistinguishable
from the controls.
In the Table it is shown that indometha-
cin treatment very significantly prolongs
survival of tumour-bearing animals. The
IF
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to explain why during the first 90 min of
incubation tumour cells produce amounts
ofPGE2very similar to thoseproducedby
isolated hepatocytes, but thereafter there
is a marked increase in PGformation.
As far as the significance of this high production ofPGsin tumoursisconcerned,
two hypotheses have been more or less
explicitly proposed. Thomas et al. (1974),
after establishing the existence of an
inverse relationship between rates of cell
proliferation and PGE biosynthesis, sug- gested that PGE may be directly involved
in the inhibition of tumour-cell growth (Santoro et al., 1976). Tumour-growth inhibition by a synthetic analogue of
PGE2 has been observed (Santoro &
Jaffe, 1979), but Lupuleseu (1978) found
an enhancement of careinogenesis after
PGE2administration.
Our data clearly indicate that, at least
in Yoshida hepatoma, PGE2 does not
appear to act on tumour cells, since cyclic AMP levels do not change during incuba-
tion and no change can be demonstrated
by incubating cells in the presence of
PGE2 (1-10 Pg/Ml). On the other hand we
have previously found that under similar
conditions adrenaline raises cyclic AMP
levels at least 2-fold (Tomasi et al., 1974). We consider more likely the hypothesis
proposed by Plescia et al. (1975) that
tumours may use PGs to subvert the
immune system. Such a role ofPGE as an
intereellular messenger also accords with
recent data obtained on liver-cell popula- tions, showing thatPGE2producedmainly in parenchymal cells acts on sinusoidal
cells by raising cyclic AMP levels (Barto-
lini et al., 1978; Tomasi et al., 1978, 1979;
Tomasi, 1976).
It is likely that the main targets of
locally released PGE2 are cells, such as
lymphocytes and (or) macrophages, which
are known to participate in the body's defence against tumour cells, and which
are known to contain PGE-sensitive
adenylate cyclases. After cyclic AMP
increase these cells become much less
sensitive to various stimuli (Pelus &
Strausser, 1977; Schultz et al., 1978).
3000
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0
Control lndomethacin Indomethacin
+PGE2
FiiG. 4.-Reversal of inhibition of growth
rate in indomethacin-treated rats by PGE2- Indomethacin was administered as
inFig. 3. PGE2 P mg/kgbodywt) dissolved
in saline was injected i.p. once a day. Con-
trol group (20 rats) indomethacin-treated
(5 rats) and indomethacin plus PGE2-
treated (5 rats) were used 6 days after
tumourimplant.
Bars represent s.e.; *P < 0-05 with
respect to control; **P < 0-05 with respect
to indomethacin-treated.
TABLE.-Effect ofindomethacin on survival .1.1
timeoftumottr-bearing rats
Survival time
+ s.e.
(days)
8-31 + 0-99
12-60 +0-got
No. of
animals
13
lot
Treatment
None
Indomethacin*
* I mg/kg body wt twice a day.
t In 3/13 rats the drug completely prevented
tumour growth.
t P < 0-05.
data do not take into account observations
that indomethacin may sometimes com-
pletely overcome the growth of the
hepatoma, thus indefinitely prolonging the life-span. Thus 5 rats injected with
hepatoma cells andreceivingindomethacin
were tumour-free after 7 days of treat-
ment, and no toxic effect of the drug was
evident after 16 days of treatment.
DISCUSSION
The datareported indicate that Yoshida
hepatoma can be included in the long list
of tumours which produce high levels of
PGs(Karim, 1976). Atpresent itis difficult346 A. TREVISANI, E. FERRETTI, A. CAPUZZO AND V. TOMASI
The effect ofnon-steroidal anti-inflammatory
drugs on tumour growth
In most studies showing raised PG levels
in tumours, indomethacin or aspirin have
been tested as anti-tumour drugs, and in
several cases they proved extremely
effective. Thus, indomethacin has been
shown both to decrease plasma or urinary
levels of PGs and to restore normal blood
calcium levels both in patients with solid
tumours and hypercalcemia (Seyberth
et al., 1975; Robertson et al., 1976) and
in hypercalcaemic mice bearing a prosta-
glandin-producing fibrosarcoma (Tashjian
et al., 1973). Immunosuppressive mouse
tumours treated in vivo or in vitro with
non-steroidal anti-inflammatory drugs lost
their capacity to suppress antibody pro-
duction (Plescia et al., 1975; Grinwich &
Plescia, 1977).
Our data clearly show that indometha-
cin or acetylsalicylic acid at low doses
markedly inhibit cell proliferation in vivo,
an effect which is paralleled by the in
vitro inhibition of PGE2 biosynthesis.
However, we are aware that this correla-
tion has to be considered cautiously, since
so manyeffects ofanti-inflammatory drugs
apparently unrelated to prostaglandin
synthesis have been reported (Flower,
1974; Kantor & Hampton, 1978).
Inthisrespect, theexperiments reported
in Fig. 4, indicating that injections of
PGE2 overcome indomethacin inhibition,
strongly suggest that inhibition of PG
synthesis and decrease of growth rate
are two closely associated events. Un-
fortunately the most direct approach to
this problem (i.e. the use of PGE2 an-
tagonists) is hampered by the lack of
potency and specificity of the available
compounds.
Since PGE2 is well known to have a
short life in the circulation, its action may
be exerted on lymphocytes or macro-
phages of the peritoneal cavity. Alterna-
tively, a circulating metabolite of PGE2
with some biological activity may be
involved in these effects.
Our data showing that indomethacin
very significantly prolongs survival of
tumour-bearing rats, as well as similar
data recently reported (Lynch & Salomon,
1979; Bennett et al., 1979) are forcing into
consideration the use of PG synthetase
inhibitors in the combined therapeutic
approach to the treatment of some
tumours, especially since indomethacin
has been reported to be non-immuno-
suppressive like other types of anti-
inflammatory drug (Plescia et al., 1975).
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